Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer.
Felipe BataliniNiya XiongNabihah TayobMadeline PolakJulia EismannLewis C CantleyGeoffrey I ShapiroViktor AdalsteinssonEric P WinerPanagiotis A KonstantinopoulosAlan D' AndreaElizabeth M SwisherUrsula A MatulonisGerburg M WulfErica L MayerPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Alpelisib in combination with olaparib is tolerable in patients with pre-treated TNBC, with evidence of activity in non-BRCA carriers. cfDNA provided important prognostic information. Results highlight potential synergistic use of a PI3K inhibitor to sensitize HR-proficient (BRCA wild-type) TNBC to PARP inhibition and suggest the potential to expand the use of PARP inhibition beyond BRCA-mutant tumors.